BioWorld

March 30, 2005

TolerRx Raises $31M In Series D To Advance Diabetes Drug TRX4

Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today) Read More

BioCurex Licenses Biomarker To Abbott In First Significant Deal

Unlike In Hollywood, Golden Rice Sequel Trumps Original

Syngenta Subject Of Inquiry Over Unapproved Corn Sales

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...